Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.80 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.80 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.77 |
| ▸ | CA1 | P00915 | 1/20 | 0.75 |
| ▸ | CA2 | P00918 | 1/20 | 0.75 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | AR | P10275 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19183376 | 1.00 | ABCG2 (0.86) | ABCG2MEN1KMT2ACXCL12CXCR4 | |
| SCHEMBL31574491 | 0.89 | CXCL12 (0.76) | ABCG2MEN1KMT2ACXCL12CXCR4 | |
| SCHEMBL30837249 | 0.89 | CXCL12 (1.00) | CXCL12CXCR4AR | |
| SCHEMBL25194287 | 0.89 | CXCL12 (1.00) | CXCL12CXCR4AR | |
| SCHEMBL12662991 | 0.89 | CXCL12 (1.00) | CXCL12CXCR4AR | |
| SCHEMBL25197185 | 0.89 | CXCL12 (1.00) | CXCL12CXCR4AR | |
| SCHEMBL30837223 | 0.89 | CXCL12 (0.76) | ABCG2MEN1KMT2ACXCL12CXCR4 | |
| SCHEMBL25194958 | 0.89 | CXCL12 (0.81) | ABCG2MEN1KMT2ACXCL12CXCR4 | |
| SCHEMBL25220029 | 0.89 | CXCL12 (0.81) | ABCG2MEN1KMT2ACXCL12CXCR4 | |
| SCHEMBL19782799 | 0.89 | CXCL12 (0.81) | ABCG2MEN1KMT2ACXCL12CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20090280483-A1 | Methods for Screening Interleukin-6 (IL-6) Signal Transduction Inhibitors | UNIVERSITY OF TOKYO, THE (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090280483-A1 | Methods for Screening Interleukin-6 (IL-6) Signal Transduction Inhibitors | UNIVERSITY OF TOKYO, THE (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | ABCG2 3643/4885MEN1 4505/4885KMT2A 4031/4885 |
| US-20090280483-A1 | Methods for Screening Interleukin-6 (IL-6) Signal Transduction Inhibitors | IL6, IL6ST, CASP6 | ABCG2 2431/4885MEN1 4655/4885KMT2A 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.